Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany

Health Policy

Volumn 84, Issue 1, 2007, Pages 30-38

  Stargardt, Tom ^a   Schreyögg, Jonas ^a,b   Busse, Reinhard ^a  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Deregulation; OTC drugs; Pharmaceutical care; Pharmacy service; Price competition

Indexed keywords

ACETYLSALICYLIC ACID; GELOMYRTOL FORTE; MYRTOL; NASENSPRAY E; NON PRESCRIPTION DRUG; PARACETAMOL; SINUPRET; UNCLASSIFIED DRUG;

ARTICLE; CONSUMER; DRUG COST; DRUG MARKETING; GERMANY; KNOWLEDGE; LAW ENFORCEMENT; PHARMACY; PROSPECTIVE PRICING; REGRESSION ANALYSIS;

COMMERCE; DATA COLLECTION; DRUGS, NON-PRESCRIPTION; ECONOMIC COMPETITION; GERMANY; GOVERNMENT REGULATION; HUMANS; LEGISLATION, DRUG; NATIONAL HEALTH PROGRAMS; PHARMACEUTICAL SERVICES; POLITICS;

EID: 34848829145     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2007.04.006     Document Type: Article

References (22)

1. Schöffski O. Die Regulierung des deutschen Apothekenwesens (1995), Nomos, Baden-Baden
2. Moen E., Toverud E., Grund J., and Brinchmann S. Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist. Pharmacy World Science 20 3 (1998) 107-112
3. Busse R., Stargardt T., and Schreyögg J. Determining the health benefit basket of the statutory health insurance in Germany. The European Journal of Health Economics 6 S1 (2005) 30-36
4. Busse R., Schreyögg J., and Henke K.-D. Pharmaceutical regulation in Germany: improving efficiency and controlling expenditures. International Journal of Health Planning and Management 20 4 (2005) 329-349
5. Anell A., and Hjelmgren J. Implementing competition in the pharmacy sector: lessons from Iceland and Norway. Applied Health Economics and Health Policy 1 3 (2002) 149-156
6. Almarsdóttir A., Morgall J., and Grimsson A. Cost containment of pharmaceutical use in Iceland: the impact of liberalization and user charges. Journal of Health Services Research & Policy 5 2 (2000) 109-113
7. Schwabe U. Nicht verschreibungspflichtige Arzneimittel. In: Schwabe U., and Paffrath D. (Eds). Arzneiverordnungsreport 2004 (2004), Springer, Berlin, Heidelberg 76-136
8. Lu Z.J., and Comanor W.S. Strategic pricing of new pharmaceuticals. The Review of Economics and Statistics 80 1 (1998) 108-118
9. ABDA. Zahlen, Daten, Fakten 2004, 2005.
10. Statistisches Landesamt Berlin. Die Zwölf Bezirke Berlins, 2004.
11. Schommer J.C., and Kucukarslan S.N. Measuring patient satisfaction with pharmaceutical services. American Journal of Health-system Pharmacy 54 23 (1997) 2721-2732
12. Finney D. Probit analysis. 3rd ed. (1977), Cambridge University Press, London
13. Aldrich J., and Nelson F. Linear probability, logit, and probit models (1984), SAGE Publications, Beverly Hills
14. Busse R., and Riesberg A. Health care system in transition - Germany (2004), European Observatory on Health Systems and Policies, Copenhagen
15. Gesundheitsberichterstattung des Bundes. Pharmacy Statistics, 2006.
16. Office of Fair Trading. The control of entry regulations and retail pharmacy services in the UK, 2003.
17. Anell A. Deregulating the pharmacy market: the case of Iceland and Norway. Health Policy 75 1 (2005) 9-17
18. Schulenburg vd.J. Management of cost and utilization of pharmaceuticals in Germany. Health Policy 41 S45 (1997) 45-53
19. Verbraucherzentralen Nordrhein-Westfalen R-PuS. Apotheken-Check 2006, 2006.
20. Mera J.A. A review of the welfare state and alternative ways of delivering health care. International Journal for Quality in Health Care 14 2 (2002) 87-90
21. Reich M.R. The politics of health sector reform in developing countries: three cases of pharmaceutical policy. Health Policy 32 1-3 (1995) 47-77
22. Mason J., Freemantle N., Nazareth I., Eccles M., Haines A., and Drummond M.F. When is it cost-effective to change the behavior of health professionals?. JAMA 286 23 (2001) 2988-2992